Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles by Yoshinobu Onuma
Based on 204 articles published since 2008
||||

Between 2008 and 2019, Yoshinobu Onuma wrote the following 204 articles about Coronary Artery Disease.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9
1 Guideline Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. 2018

Byrne, Robert A / Stefanini, Giulio G / Capodanno, Davide / Onuma, Yoshinobu / Baumbach, Andreas / Escaned, Javier / Haude, Michael / James, Stefan / Joner, Michael / Jüni, Peter / Kastrati, Adnan / Oktay, Semih / Wijns, William / Serruys, Patrick W / Windecker, Stephan. ·Deutsches Herzzentrum München, Technische Universität München, Germany. ·EuroIntervention · Pubmed #28948934.

ABSTRACT: A previous Task Force of the European Society of Cardiology (ESC) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) provided a report on recommendations for the non-clinical and clinical evaluation of coronary stents. Following dialogue with the European Commission, the Task Force was asked to prepare an additional report on the class of devices known as bioresorbable scaffolds (BRS). Five BRS have CE-mark approval for use in Europe. Only one device -the Absorb bioresorbable vascular scaffold- has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2-3 years. For this reason, at present BRS should not be preferred to conventional DES in clinical practice. The Task Force recommends that new BRS devices should undergo systematic non-clinical testing according to standardized criteria prior to evaluation in clinical studies. A clinical evaluation plan should include data from a medium sized, randomized trial against DES powered for a surrogate end point of clinical efficacy. Manufacturers of successful devices receive CE- mark approval for use and must have an approved plan for a large-scale randomized clinical trial with planned long-term follow-up.

2 Editorial Data from real-world registries: can it guide development of the bioresorbable scaffolds of tomorrow? 2017

Brugaletta, Salvatore / Ortega-Paz, Luis / Onuma, Yoshinobu. ·Cardiovascular Institute, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ·EuroIntervention · Pubmed #29260716.

ABSTRACT: -- No abstract --

3 Editorial Snowshoe Versus Ice Skate for Scaffolding of Disrupted Vessel Wall. 2015

Serruys, Patrick W / Suwannasom, Pannipa / Nakatani, Shimpei / Onuma, Yoshinobu. ·International Center for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, United Kingdom. Electronic address: patrick.w.j.c.serruys@gmail.com. · Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands. ·JACC Cardiovasc Interv · Pubmed #26088509.

ABSTRACT: -- No abstract --

4 Editorial Unravelling the complexities of the coronary bifurcation: is this raising a few eyebrows? 2012

Farooq, Vasim / Okamura, Takayuki / Onuma, Yoshinobu / Gogas, Bill D / Serruys, Patrick W. · ·EuroIntervention · Pubmed #22334311.

ABSTRACT: -- No abstract --

5 Editorial Transferability of data between different drug-eluting stents. 2009

Magro, Michael / Onuma, Yoshinobu / Silber, Sigmund / Serruys, Patrick W. · ·EuroIntervention · Pubmed #20142170.

ABSTRACT: -- No abstract --

6 Review Imaging-guided pre-dilatation, stenting, post-dilatation: a protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds. 2018

Ali, Ziad A / Karimi Galougahi, Keyvan / Shlofmitz, Richard / Maehara, Akiko / Mintz, Gary S / Abizaid, Alexandre / Chamié, Daniel / Hill, Jonathan / Serruys, Patrick W / Onuma, Yoshinobu / Stone, Gregg W. ·a Clinical Trials Center, Cardiovascular Research Foundation , New York , NY , USA. · b Department of Cardiology , NewYork-Presbyterian Hospital/Columbia University Medical Center , New York , NY , USA. · c Department of Cardiology , St Francis Hospital , Roslyn , NY , USA. · d Department of Cardiology , Instituto Dante Pazzanese of Cardiology , São Paulo , Brazil. · e Department of Cardiology , Cardiovascular Research Center , São Paulo , Brazil. · f Department of Cardiology , King's College , London , UK. · g Imperial College of Science, Technology and Medicine , London , UK. · h Thoraxcenter, Erasmus Medical Center , Rotterdam , The Netherlands. ·Expert Rev Cardiovasc Ther · Pubmed #29732926.

ABSTRACT: INTRODUCTION: The advent of the fully bioresorbable vascular scaffold (BVS) is the latest step in a series of advancements in the design of intracoronary stents over the past few decades. The novelty of this technology is in providing temporary vessel scaffolding and local antiproliferative therapy to prevent neointimal hyperplasia after percutaneous coronary intervention followed by gradual resorption of the scaffold to restore the native vessel anatomy and physiology - a process termed vascular reparative therapy. Areas covered: The first generation of BVS has not been able to fully match the high benchmark in safety and efficacy set by contemporary metallic drug-eluting stents. These shortcomings of BVS may be due to factors related to the device itself, the complexity of the underlying lesion, or the implantation technique. Expert commentary: Here, how intravascular imaging may be used to minimize these shortcomings is described and moreover, an imaging-guided step-by-step approach for BVS implantation that integrates the recently described pre-dilatation, stenting, post-dilatation (PSP) strategy is explained.

7 Review Imaging assessment of bioresorbable vascular scaffolds. 2018

Sotomi, Yohei / Suwannasom, Pannipa / Tenekecioglu, Erhan / Collet, Carlos / Nakatani, Shimpei / Okamura, Takayuki / Muramatsu, Takashi / Ishibashi, Yuki / Tateishi, Hiroki / Miyazaki, Yosuke / Asano, Taku / Katagiri, Yuki / von Zur Muehlen, Constantin / Tanabe, Kengo / Kozuma, Ken / Ozaki, Yukio / Serruys, Patrick W / Onuma, Yoshinobu. ·Department of Cardiology, Osaka Police Hospital, Osaka, Japan. · Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. · Faculty of Medicine, Northern Region Heart Center, Chiang Mai University, Chiang Mai, Thailand. · ThoraxCenter, Erasmus Medical Center, Rotterdam, The Netherlands. · Division of Cardiology, Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan. · Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan. · Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan. · Faculty of Medicine, Heart Center Freiburg University, University of Freiburg, Freiburg, Germany. · Division of Cardiology, Cardiac Intensive Care Unit, Mitsui Memorial Hospital, Tokyo, Japan. · Teikyo University Hospital, Tokyo, Japan. · NHLI, Imperial College London, London, UK. patrick.w.j.c.serruys@gmail.com. · , P.O. Box 2125, 3000 CC, Rotterdam, The Netherlands. patrick.w.j.c.serruys@gmail.com. · Cardialysis, Rotterdam, The Netherlands. ·Cardiovasc Interv Ther · Pubmed #28766253.

ABSTRACT: Vascular reparative therapy has become a reality with bioresorbable scaffolds (BRSs). To assess acute and long-term performance of the device, multimodality imaging would be essential. Radiopacity of metal hinders the imaging assessment, whereas radiolucent polymeric scaffolds allow for a precise imaging assessment with either invasive or non-invasive modality at baseline and at follow-up, which is one of the advantages of polymeric BRSs. Recent large trials evaluating clinical results of the first-generation BRS technology raised concerns about the safety and efficacy of these devices, namely, scaffold thrombosis. Intensive research with multimodality imaging in the field is being conducted to have in-depth understanding of the issues, which will facilitate the improvement of implantation techniques and the development of the next-generation BRSs. The current review focuses on the clinical application of the imaging modalities to assess the short- and long-term performance of the Absorb BVS.

8 Review State of the art: the inception, advent and future of fully bioresorbable scaffolds. 2017

Katagiri, Yuki / Stone, Gregg W / Onuma, Yoshinobu / Serruys, Patrick W. ·Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. ·EuroIntervention · Pubmed #28844034.

ABSTRACT: To overcome the limitations of metallic stents, the development of the bioresorbable vascular scaffold started about 30 years ago. Researchers anticipated a transformative revolution from "vascular reparative therapy" by BRS at the beginning of its development. To date, there are five commercially available bioresorbable scaffolds which have already gained CE mark. However, recent studies, including randomised trials and meta-analyses evaluating clinical results of BRS, have raised concerns about the safety and efficacy of the device in the first few years prior to its complete bioresorption, compared to contemporary metallic DES. As one of the efforts to address these concerns, the impact of implantation technique was investigated. In addition, there are several aspects to be improved such as mechanical integrity, strut configuration, and late structural discontinuity. Intensive researches into the underlying causes of the greater device thrombosis rates with BRS have stimulated improvement of implantation technique and the development of next-generation BRS. Just as we have witnessed the evolution from first- to second-generation metallic DES, we anticipate that future generations of BRS with thinner struts and enhanced mechanical properties will result in substantially improved intermediate-term outcomes and safety.

9 Review State of the art: coronary angiography. 2017

Collet, Carlos / Grundeken, Maik J / Asano, Taku / Onuma, Yoshinobu / Wijns, William / Serruys, Patrick W. ·Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. ·EuroIntervention · Pubmed #28844026.

ABSTRACT: In the early days of coronary angiography, the precise quantification of luminal narrowing was challenging. The introduction of balloon angioplasty (percutaneous transluminal coronary angioplasty [PTCA]) by Andreas Grüntzig in 1977 was perhaps the greatest incentive to the development of quantitative coronary angiography (QCA). QCA has played a crucial role in evaluating interventional techniques and assessing the results of new technologies. With the advent of drug-eluting stents (DES), QCA metrics such as late lumen loss and diameter stenosis (restenosis) proved to be instrumental in assessing new technologies. Refinements in QCA with the advent of dedicated bifurcation analysis and three-dimensional (3D) QCA have broadened the application of QCA. Beyond angiographic metrics, new developments in the field of QCA have introduced the functional component in the assessment of coronary lesions. Angiography-derived fractional flow reserve (FFR) may be a good tool for diagnosing ischaemia-producing lesions in patients with non-complex coronary artery disease. Furthermore, the incremental functional information can be used to expand the traditional late lumen loss (LLL) and restenosis concepts.

10 Review 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. 2017

Ali, Ziad A / Serruys, Patrick W / Kimura, Takeshi / Gao, Runlin / Ellis, Stephen G / Kereiakes, Dean J / Onuma, Yoshinobu / Simonton, Charles / Zhang, Zhen / Stone, Gregg W. ·New York Presbyterian Hospital, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA. · International Centre for Cardiovascular Health, Imperial College, London, London, UK. · Kyoto University Hospital, Kyoto, Japan. · Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China. · Cleveland Clinic, Cleveland, OH, USA. · The Christ Hospital, Heart and Vascular Center, Lindner Research Center, Cincinnati, OH, USA. · Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands. · Abbott Vascular, Santa Clara, CA, USA. · New York Presbyterian Hospital, Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY, USA. Electronic address: gs2184@columbia.edu. ·Lancet · Pubmed #28732815.

ABSTRACT: BACKGROUND: Bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention after their complete bioresorption. Randomised trials have shown non-inferiority between BVS and metallic drug-eluting stents at 1 year in composite safety and effectiveness outcomes, although some increases in rates of target vessel-related myocardial infarction and device thrombosis were identified. Outcomes of BVS following the first year after implantation are unknown. We sought to ascertain whether BVS are as safe and effective as drug-eluting stents within 2 years after implantation and between 1 and 2 years. METHODS: We did a systematic review and meta-analysis of randomised trials in which patients were randomly assigned to everolimus-eluting Absorb BVS or metallic everolimus-eluting stents (EES) and followed up for at least 2 years. We searched MEDLINE, the Cochrane database, TCTMD, ClinicalTrials.gov, Clinical Trial Results, CardioSource, and abstracts and presentations from major cardiovascular meetings up to April 1, 2017, to identify relevant studies. The primary efficacy outcome measure was the device-oriented composite endpoint (cardiac mortality, target vessel-related myocardial infarction, or ischaemia-driven target lesion revascularisation) and the primary safety outcome measure was definite or probable device thrombosis. Individual patient data from the four ABSORB trials were used for landmark and subgroup analysis and multivariable modelling. FINDINGS: We identified seven randomised trials in which 5583 patients were randomly assigned to Absorb BVS (n=3261) or metallic EES (n=2322) and followed up for 2 years. BVS had higher 2-year relative risks of the device-oriented composite endpoint than did EES (9·4% [304 of 3217] vs 7·4% [169 of 2299]; relative risk [RR] 1·29 [95% CI 1·08-1·56], p=0·0059). These differences were driven by increased rates of target vessel-related myocardial infarction (5·8% [187 of 3218] vs 3·2% [74 of 2299]; RR 1·68 [95% CI 1·29-2·19], p=0·0003) and ischaemia-driven target lesion revascularisation (5·3% [169 of 3217] vs 3·9% [90 of 2300]; 1·40 [1·09-1·80], p=0·0090) with BVS, with non-significant differences in cardiac mortality. The cumulative 2-year incidence of device thrombosis was higher with BVS than with EES (2·3% [73 of 3187] vs 0·7% [16 of 2281]; RR 3·35 [95% CI 1·96-5·72], p<0·0001). Landmark analysis between 1 and 2 years also showed higher rates of the device-oriented composite endpoint (3·3% [69 of 2100] vs 1·9% [23 of 1193]; RR 1·64 [95% CI 1·03-2·61], p=0·0376) and device thrombosis (0·5% [11 of 2085] vs none [0 of 1183], p<0·0001) in BVS-treated patients than in EES-treated patients. INTERPRETATION: BVS was associated with increased rates of composite device-oriented adverse events and device thrombosis cumulatively at 2 years and between 1 and 2 years of follow-up compared with EES. FUNDING: Abbott Vascular.

11 Review Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. 2017

Collet, Carlos / Asano, Taku / Miyazaki, Yosuke / Tenekecioglu, Erhan / Katagiri, Yuki / Sotomi, Yohei / Cavalcante, Rafael / de Winter, Robbert J / Kimura, Takeshi / Gao, Runlin / Puricel, Serban / Cook, Stéphane / Capodanno, Davide / Onuma, Yoshinobu / Serruys, Patrick W. ·Department of Cardiology, Academic Medical Center, Universiteit van Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam-Zuidoost, Netherlands. · Department of Interventional Cardiology, 's-Gravendijkwal 230, 3015 CE Rotterdam, Netherlands. · Department of Cardiovascular Medicine, Kyoto University Hospital, Shogoin Kawaharacho, Sakyo Ward, Kyoto, Kyoto Prefecture 606-8507, Japan. · Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, 10 Beijing, China. · Department of Cardiology, Fribourg University and Hospital, Avenue de l'Europe 20, 1700 Fribourg, Switzerland. · Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Via Salvatore Citelli, 6, 95124 Catania CT, Italy. · Imperial Department of Medicine, Imperial College of London, Kensington, London SW7 2AZ, UK. ·Eur Heart J · Pubmed #28430908.

ABSTRACT: Aims: To compare the long-term safety and efficacy of bioresorbable vascular scaffold (BVS) with everolimus-eluting stent (EES) after percutaneous coronary interventions. Methods and results: A systematic review and meta-analysis of randomized clinical trials comparing clinical outcomes of patients treated with BVS and EES with at least 24 months follow-up was performed. Adjusted random-effect model by the Knapp-Hartung method was used to compute odds ratios (OR) and 95% confidence intervals (CI). The primary safety outcome of interest was the risk of definite/probable device thrombosis (DT). The primary efficacy outcome of interest was the risk of target lesion failure (TLF). Five randomized clinical trials (n = 1730) were included. Patients treated with Absorb BVS had a higher risk of definite/probable DT compared with patients treated with EES (OR 2.93, 95%CI 1.37-6.26, P = 0.01). Very late DT (VLDT) occurred in 13 patients [12/996 (1.4%, 95%CI: 0.08-2.5) Absorb BVS vs. 1/701 (0.5%, 95%CI: 0.2-1.6) EES; OR 3.04; 95%CI 1.2-7.68, P = 0.03], 92% of the VLDT in the BVS group occurred in the absence of dual antiplatelet therapy (DAPT). Patients treated with Absorb BVS had a trend towards higher risk of TLF (OR 1.48, 95%CI 0.90-2.42, P = 0.09), driven by a higher risk of target vessel myocardial infarction and ischaemia-driven target lesion revascularization. No difference was found in the risk of cardiac death. Conclusion: Compared with EES, the use of Absorb BVS was associated with a higher rate of DT and a trend towards higher risk of TLF. VLDT occurred in 1.4% of the patients, the majority of these events occurred in the absence of DAPT.

12 Review Bioresorbable Scaffold: The Emerging Reality and Future Directions. 2017

Sotomi, Yohei / Onuma, Yoshinobu / Collet, Carlos / Tenekecioglu, Erhan / Virmani, Renu / Kleiman, Neal S / Serruys, Patrick W. ·From the Department of Cardiology, Academic Medical Center, University of Amsterdam, the Netherlands (Y.S., C.C.) · ThoraxCenter, Erasmus Medical Center, Rotterdam, the Netherlands (Y.O., E.T.) · Cardialysis, Rotterdam, the Netherlands (Y.O.) · CVPath, Institute Inc, Gaithersburg, MD (R.V.) · Department of Cardiology (NSK), Houston Methodist DeBakey Heart and Vascular Center, Texas (N.S.K.) · and NHLI, Imperial College London, United Kingdom (P.W.S.). ·Circ Res · Pubmed #28408454.

ABSTRACT: In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown excellent clinical results. However, even the latest-generation drug-eluting stent has not managed to address all the limitations of permanent metallic coronary stents, such as the risks of target lesion revascularization, neoatherosclerosis, preclusion of late lumen enlargement, and the lack of reactive vasomotion. Furthermore, the risk of very late stent, although substantially reduced with newer-generation drug-eluting stent, still remains. These problems were anticipated to be solved with the advent of fully biodegradable devices. Fully bioresorbable coronary scaffolds have been designed to function transiently to prevent acute recoil, but have retained the capability to inhibit neointimal proliferation by eluting immunosuppressive drugs. Nevertheless, long-term follow-up data of the leading bioresorbable scaffold (Absorb) are becoming available and have raised a concern about the relatively higher incidence of scaffold thrombosis. To reduce the rate of clinical events, improvements in the device, as well as implantation procedure, are being evaluated. This review will focus on the current CE-mark approved bioresorbable scaffolds, their basic characteristics, and clinical results. In addition, we summarize the current limitations of bioresorbable scaffold and their possible solutions.

13 Review Intravascular multimodality imaging: feasibility and role in the evaluation of coronary plaque pathology. 2017

Michail, Michael / Serruys, Patrick W / Stettler, Rodrigue / Crake, Tom / Torii, Ryo / Tenekecioglu, Erhan / Zeng, Yaping / Onuma, Yoshinobu / Mathur, Anthony / Bourantas, Christos V. ·Barts Heart Centre, Barts Health NHS Trust, London, UK. · Faculty of Medicine, National Heart & Lung Institute, Imperial College London, UK. · Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands. · Department of Mechanical Engineering, University College London, UK. · Department of Cardiovascular Sciences, University College London, UK. ·Eur Heart J Cardiovasc Imaging · Pubmed #28329320.

ABSTRACT: Coronary artery disease remains the leading cause of death in the developed world. Over recent years, research has been focused on the development of diagnostic intravascular imaging techniques that enable assessment of plaque composition and morphology, and allow identification of vulnerable, high-risk lesions. Nevertheless recent studies of coronary atherosclerosis have shown that invasive modalities have a limited accuracy in detecting lesions that will progress and cause events, whilst histology-based studies also highlighted the limitations of invasive imaging in assessing plaque characteristics. To overcome these drawbacks, multimodality imaging has been proposed. Although it is apparent that coronary imaging with two or three imaging modalities is time consuming and is associated with a risk of complications, evidence from small clinical studies demonstrated that it provides incremental information about plaque pathology and biology and underscored the need to develop dual-probe hybrid imaging catheters that would enable complete and comprehensive assessment of plaque morphology. This paper reviews the current clinical evidence that supports the use of multimodality intravascular imaging in the study of atherosclerosis, summarizes the key findings of the first invasive imaging studies that utilize hybrid dual-probe catheters, and discusses the limitations of combined intravascular imaging that restrict its broad application in both the clinical and research arena.

14 Review Single or dual antiplatelet therapy after PCI. 2017

Miyazaki, Yosuke / Suwannasom, Pannipa / Sotomi, Yohei / Abdelghani, Mohammad / Tummala, Karthik / Katagiri, Yuki / Asano, Taku / Tenekecioglu, Erhan / Zeng, Yaping / Cavalcante, Rafael / Collet, Carlos / Onuma, Yoshinobu / Serruys, Patrick W. ·Erasmus University Medical Center, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. · Academic Medical Center, Meibergdreef 9, B2-127, 1105 AZ Amsterdam, The Netherlands. · Northern Region Heart Center, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, 110 Intavaroros Road, Sripoom District, Muang, Chiang Mai, 50200, Thailand. · Department of Cardiology, Siddhartha Medical College and Government General Hospital, Ring Road, Gunadala, Vijayawada-520 008, Andhra Pradesh, India. · Cardialysis, Westblaak 98, 3012 KM, Rotterdam, The Netherlands. · Imperial College London, Kensington, London SW7 2AZ, UK. ·Nat Rev Cardiol · Pubmed #28181585.

ABSTRACT: The optimal duration and type of antiplatelet therapy after implantation of a drug-eluting stent (DES) remains uncertain. At the time of the first-in-man implantation of the sirolimus DES in 1999, the protocol-defined dual antiplatelet therapy (DAPT) duration was only 2 months. Subsequently, DAPT duration was extended to 1 year on the basis of anecdotal historical data, and this practice was then incorporated into clinical guidelines. For >1 decade, trialists have sought to compare the safety and efficacy of abbreviated (<6 months) and prolonged (>12 months) DAPT regimens. However, the body of evidence is limited by the heterogeneity of end points, time of randomization, and bleeding criteria used in each trial. Pharmaceutical advances led to the introduction of new ADP-receptor antagonists, which are thought to be more effective than clopidogrel. The ADP-receptor antagonists moved the focus from the optimal duration of DAPT to the potential efficacy of single antiplatelet therapy after DES implantation. In this Review, we summarize the current evidence on the duration of DAPT and the risk of bleeding and adverse cardiac events after DES implantation, and describe the pitfalls of trial interpretation. The ongoing, prospective trials to test single antiplatelet therapy after DES implantation are also discussed.

15 Review Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. 2017

Tenekecioglu, Erhan / Albuquerque, Felipe N / Sotomi, Yohei / Zeng, Yaping / Suwannasom, Pannipa / Tateishi, Hiroki / Cavalcante, Rafael / Ishibashi, Yuki / Nakatani, Shimpei / Abdelghani, Mohammad / Dijkstra, Jouke / Bourantas, Christos / Collet, Carlos / Karanasos, Antonios / Radu, Maria / Wang, Ancong / Muramatsu, Takashi / Landmesser, Ulf / Okamura, Takayuki / Regar, Evelyn / Räber, Lorenz / Guagliumi, Giulio / Pyo, Robert T / Onuma, Yoshinobu / Serruys, Patrick W. ·Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands. · Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, United States. · Academic Medical Center-University of Amsterdam, Amsterdam, The Netherlands. · Leiden University Medical Center, Leiden, The Netherlands. · University College of London Hospitals, London, United Kingdom. · Copenhagen University Hospital, Copenhagen, Denmark. · Fujita Health University Hospital, Toyoake, Japan. · Charite Universitätsmedizin Berlin, Berlin, Germany. · Yamaguchi University, Yamaguchi, Japan. · Department of Cardiovascular Surgery, University Hospital Zürich, Switzerland. · Bern University Hospital, Bern, Switzerland. · Ospedali Riuniti di Bergamo, Bergamo, Italy. · Albert Einstein College of Medicine, Montefiore Medical Center, NY. · International Centre for Circulatory Health, Imperial College, London, United Kingdom. ·Catheter Cardiovasc Interv · Pubmed #28109054.

ABSTRACT: By providing valuable information about the coronary artery wall and lumen, intravascular imaging may aid in optimizing interventional procedure results and thereby could improve clinical outcomes following percutaneous coronary intervention (PCI). Intravascular optical coherence tomography (OCT) is a light-based technology with a tissue penetration of approximately 1 to 3 mm and provides near histological resolution. It has emerged as a technological breakthrough in intravascular imaging with multiple clinical and research applications. OCT provides detailed visualization of the vessel following PCI and provides accurate assessment of post-procedural stent performance including detection of edge dissection, stent struts apposition, tissue prolapse, and healing parameters. Additionally, it can provide accurate characterization of plaque morphology and provides key information to optimize post-procedural outcomes. This manuscript aims to review the current clinical and research applications of intracoronary OCT and summarize the analytic OCT imaging software packages currently available. © 2017 Wiley Periodicals, Inc.

16 Review Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology. 2016

Chamié, Daniel / Garcia-Garcia, Hector / Costa, Ricardo A / Onuma, Yoshinobu / Abizaid, Alexandre / Serruys, Patrick W. ·Department of Interventional Cardiology, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil. daniel.chamie@gmail.com. · Cardiovascular Research Center, Sao Paulo, Brazil. daniel.chamie@gmail.com. · Department of Interventional Cardiology, MedStar Heart and Vascular Institute, Washington, DC. · Department of Interventional Cardiology, Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil. · Cardiovascular Research Center, Sao Paulo, Brazil. · Department of Interventional Cardiology, Erasmus University Medical Center, Thoraxcenter, Rotterdam, The Netherlands. · Cardialysis BV, Rotterdam, The Netherlands. · Hospital Israelita Albert Einstein, Sao Paulo, Brazil. · NHLI, Imperial College London, International Centre for Circulatory Health, London, United Kingdom. ·Catheter Cardiovasc Interv · Pubmed #27797463.

ABSTRACT: Fully bioresorbable scaffolds (BRS) represent a novel approach for the percutaneous treatment of coronary artery stenosis, providing temporary vessel scaffolding with drug-eluting capability during the restenosis-prone phase of the vascular healing. Beyond this initial critical period, when mechanical scaffolding support is no longer necessary, the device is bioresorbed, restoring the normal vascular physiology with the aim to eliminate the long-term safety concerns related to permanent metallic implants. Nonetheless, current BRS technology suffers from limited mechanical properties as compared to available metallic platforms, requiring careful attention to lesion preparation, accurate vessel sizing, and implantation technique. Intravascular imaging has played an important role in providing knowledge on the acute effects after BRS deployment, and it helped refine the current technique of BRS implantation. In addition, extensive work with multiple intravascular imaging modalities have also contributed to the understanding of the unique dynamic vascular changes that are experienced in the treated segment from post-implantation up to complete device bioresorption. In this manuscript, we review the role of invasive imaging modalities-from angiography to sound- and light-based techniques-to guide BRS implantation procedures, to assess its acute results postimplantation, and the changes experienced in the long-term until complete bioresorption has ensued. © 2016 Wiley Periodicals, Inc.

17 Review Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds. 2016

Tenekecioglu, Erhan / Bourantas, Christos V / Abdelghani, Mohammad / Sotomi, Yohei / Suwannasom, Pannipa / Tateishi, Hiroki / Onuma, Yoshinobu / Yılmaz, Mustafa / Serruys, Patrick W. ·a Department of Cardiology, ThoraxCentre , Erasmus Medical Center , Rotterdam , The Netherlands. · b Institute of Cardiovascular Sciences , University College of London , London , UK. · c Department of Cardiology , Barts Health NHS Trust , London , UK. · d Academic Medical Center , University of Amsterdam , Amsterdam , The Netherlands. · e Department of Cardiology , Bursa Postgraduate Research and Education Hospital , Bursa , Turkey. · f International Centre for Circulatory Health , Imperial College , London , UK. ·Expert Rev Cardiovasc Ther · Pubmed #27376592.

ABSTRACT: INTRODUCTION: With new developments in percutaneous coronary intervention (PCI), such as the introduction of bioresorbable scaffolds (BRS), percutaneous treatment of coronary artery diseases has entered a new era. Without metallic remnants, BRSs appear able to overcome several limitations of the existing metallic stents and provide a physiologic treatment of coronary artery pathology. AREAS COVERED: BRS have different mechanical properties compared to the traditional metallic stents that should be taken into account during their implantation. Lesion selection, device sizing and satisfied pre-dilatation should be implemented prudently. Although intravascular imaging is not mandatory for the implantation of BRSs it may have a value in optimizing device deployment assess final results and reduce the risk of device related adverse events such as re-stenosis, or scaffold thrombosis. This review aims to reveal the crucial points about the methods of optimization in each steps of BRS implantation. Expert commentary: The target lesions for BRS should be selected meticulously. Pre-dilatation, post-dilatation and intra-vascular imaging techniques should be implemented appropriately to avoid undesirable events after scaffold implantation.

18 Review Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. 2016

Tenekecioglu, Erhan / Farooq, Vasim / Bourantas, Christos V / Silva, Rafael Cavalcante / Onuma, Yoshinobu / Yılmaz, Mustafa / Serruys, Patrick W. ·ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. erhantenekecioglu@yahoo.com. · Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University, Hospitals NHS Trust, Manchester, UK. vasimfarooq@hotmail.com. · Institute of Cardiovascular Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. vasimfarooq@hotmail.com. · Institute of Cardiovascular Sciences, University College of London, London, UK. cbourantas@gmail.com. · Department of Cardiology, Barts Health NHS Trust, London, UK. cbourantas@gmail.com. · ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. rafacavasi@hotmail.com. · ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. yoshinobuonuma@gmail.com. · Department of Cardiology, Bursa Postgraduate Education and Research Hospital, Bursa, Turkey. mustafayih@yahoo.com.tr. · ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. patrick.w.j.c.serruys@gmail.com. · International Centre for Circulatory Health, Imperial College, London, UK. patrick.w.j.c.serruys@gmail.com. · Interventional Cardiology Department, Erasmus MC, 's-Gravendijkwal 230, Rotterdam, 3015 CE, The Netherlands. patrick.w.j.c.serruys@gmail.com. ·BMC Cardiovasc Disord · Pubmed #26868826.

ABSTRACT: Numerous advances and innovative therapies have been introduced in interventional cardiology over the recent years, since the first introduction of balloon angioplasty, but bioresorbable scaffold is certainly one of the most exciting and attracting one. Despite the fact that the metallic drug-eluting stents have significantly diminished the re-stenosis ratio, they have considerable limitations including the hypersensitivity reaction to the polymer that can cause local inflammation, the risk of neo-atherosclerotic lesion formation which can lead to late stent failure as well as the fact that they may preclude surgical revascularization and distort vessel physiology. Bioresorbable scaffolds overcome these limitations as they have the ability to dissolve after providing temporary scaffolding which safeguards vessel patency. In this article we review the recent developments in the field and provide an overview of the devices and the evidence that support their efficacy in the treatment of CAD. Currently 3 devices are CE marked and in clinical use. Additional 24 companies are developing these kind of coronary devices. Most frequently used material is PLLA followed by magnesium.

19 Review Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. 2014

Zhang, Yaojun / Tian, Nailiang / Dong, Shengjie / Ye, Fei / Li, Minghui / Bourantas, Christos V / Iqbal, Javaid / Onuma, Yoshinobu / Muramatsu, Takashi / Diletti, Roberto / Garcia-Garcia, Hector M / Xu, Bo / Serruys, Patrick W / Chen, Shaoliang. ·Thoraxcenter, Erasmus Medical Center, Rotterdam, 3015CE, The Netherlands. · Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China. · Soochow University, Suzhou, Jiangsu 215021, China. · Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing 100037, China. · Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China. Email: chmengx126@gmail.com. ·Chin Med J (Engl) · Pubmed #24890171.

ABSTRACT: BACKGROUND: Drug eluting stents (DESs) made with biodegradable polymer have been developed in an attempt to improve clinical outcomes. However, the impact of biodegradable polymers on clinical events and stent thrombosis (ST) remains controversial. METHODS: We searched Medline, the Cochrane Library and other internet sources, without language or date restrictions for articles comparing clinical outcomes between biodegradable polymer DES and durable polymer DES. Safety endpoints were ST (definite, definite/probable), mortality, and myocardial infarction (MI). Efficacy endpoints were major adverse cardiac event (MACE) and target lesion revascularization (TLR). RESULTS: We identified 15 randomized controlled trials (n = 17 068) with a weighted mean follow-up of 20.6 months. There was no statistical difference in the incidence of definite/probable ST between durable polymer- and biodegradable polymer- DES; relative risk (RR) 0.83; 95% confidence interval (CI) 0.62-1.11; P = 0.22. Biodegradable polymer DES had similar rates of definite ST (RR 0.94, 95% CI 0.66-1.33, P = 0.72), mortality (RR 0.94, 95% CI 0.82-1.09, P = 0.43), MI (RR 1.08, 95% CI 0.92-1.26. P = 0.35), MACE (RR 0.99, 95% CI 0.91-1.09, P = 0.85), and TLR (RR, 0.94, 95% CI 0.83-1.06, P = 0.30) compared with durable polymer DES. Based on the stratified analysis of the included trials, the treatment effect on definite ST was different at different follow-up times: ≤ 1 year favoring durable polymer DES and >1 year favoring biodegradable polymer DES. CONCLUSIONS: Biodegradable polymer DES has similar safety and efficacy for treating patients with coronary artery disease compared with durable polymer DES. Further data with longer term follow-up are warranted to confirm the potential benefits of biodegradable polymer DES.

20 Review Bioresorbable drug-eluting magnesium-alloy scaffold for treatment of coronary artery disease. 2013

Campos, Carlos M / Muramatsu, Takashi / Iqbal, Javaid / Zhang, Ya-Jun / Onuma, Yoshinobu / Garcia-Garcia, Hector M / Haude, Michael / Lemos, Pedro A / Warnack, Boris / Serruys, Patrick W. ·Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam 3015 GD, The Netherlands. p.w.j.c.serruys@erasmusmc.nl. ·Int J Mol Sci · Pubmed #24351829.

ABSTRACT: The introduction of metallic drug-eluting stents has reduced the risk of restenosis and widened the indications of percutaneous coronary intervention in treatment of coronary artery disease. However, this medical device can induce hypersensitive reaction that interferes with the endothelialization and healing process resulting in late persistent or acquired malapposition of the permanent metallic implant. Delayed endotheliaization and malapposition may lead to late and very late stent thrombosis. Bioresorbable scaffolds (BRS) have been introduced to potentially overcome these limitations, as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage. Magnesium is an essential mineral needed for a variety of physiological functions in the human body and its bioresorbable alloy has the strength-to-weight ratio comparable with that of strong aluminum alloys and alloy steels. The aim of this review is to present the new developments in Magnesium BRS technology, to describe its clinical application and to discuss the future prospects of this innovative therapy.

21 Review Bioresorbable scaffolds: current knowledge, potentialities and limitations experienced during their first clinical applications. 2013

Bourantas, Christos V / Onuma, Yoshinobu / Farooq, Vasim / Zhang, Yaojun / Garcia-Garcia, Hector M / Serruys, Patrick W. ·Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands. ·Int J Cardiol · Pubmed #22748288.

ABSTRACT: The traditional metallic stents have significant limitations as they predispose to late thrombosis, may preclude surgical revascularization and distort vessel physiology. Bioresorbable scaffolds (BRSs) are a relatively new technology introduced to overcome these drawbacks. The potential of these devices as well as the reported results from their clinical applications attracted interest and drove research and industry towards the development of new BRSs and the improvement of the existing devices. Thus, over the last years considerable progress has been made and today numerous BRSs are available. The aim of this review article is to highlight the potentialities of these devices, describe the evidence from the recent clinical trials and discuss the advantages, limitations and concerns that were aroused during the first implementation of BRSs in clinical arena.

22 Review Bioresorbable scaffolds: current evidence and ongoing clinical trials. 2012

Bourantas, Christos V / Zhang, Yaojun / Farooq, Vasim / Garcia-Garcia, Hector M / Onuma, Yoshinobu / Serruys, Patrick W. ·Thoraxcenter, Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. ·Curr Cardiol Rep · Pubmed #22810889.

ABSTRACT: Bioresorbable scaffolds (BRS) represent a novel approach in coronary stent technology. In contrast to the metallic stents, they provide transient scaffolding, thereby safeguarding early vessel patency and acute gain. Subsequently a process of "decomposition" occurs, that results in the complete absorption of the scaffold. This reduces the risk of late complications, allowing the vessel to maintain its integrity and physiological function. This unique ability has attracted interest and nowadays several BRS are available. The aim of this review article is to describe the advances in the field, present the evidence from the preclinical and clinical evaluation of these devices, and provide an overview of the ongoing clinical trials that were designed to examine the effectiveness of BRS in the clinical setting.

23 Review The ABSORB bioresorbable vascular scaffold: an evolution or revolution in interventional cardiology? 2012

Gogas, Bill D / Farooq, Vasim / Onuma, Yoshinobu / Serruys, Patrick W. ·Thoraxcenter, Erasmus University Medical Centre, Rotterdam, the Netherlands. ·Hellenic J Cardiol · Pubmed #22796817.

ABSTRACT: -- No abstract --

24 Review Freeing the vessel from metallic cage: what can we achieve with bioresorbable vascular scaffolds? 2012

Onuma, Yoshinobu / Muramatsu, Takashi / Kharlamov, Alexander / Serruys, Patrick W. ·Thoraxcenter, Erasmus Medical Center, 's Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. ·Cardiovasc Interv Ther · Pubmed #22569783.

ABSTRACT: -- No abstract --

25 Review Tools & techniques: risk stratification and diagnostic tools in left main stem intervention. 2011

Farooq, Vasim / Heo, Jung Ho / Räber, Lorenz / Brugaletta, Salvatore / Radu, Maria / Gogas, Bill D / Diletti, Roberto / Onuma, Yoshinobu / Garcia-Garcia, Hector M / Serruys, Patrick W. ·Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, Rotterdam, The Netherlands. ·EuroIntervention · Pubmed #21986332.

ABSTRACT: -- No abstract --

Next